Showing results (201-210 of 285) with videos related to
Sort By:
Pageof 29
Gastroenterology|January 1, 2008
Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosisRami Moucari, Tarik Asselah, Dominique Cazals-Hatem, et al.Hepatology (Baltimore, Md.)|June 19, 2012
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trialsPatrick Marcellin, Hugo Cheinquer, Manuela Curescu, et al.Journal of Clinical Gastroenterology|February 28, 2013
Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatmentPatrick Marcellin, Antonio Craxi, Carlos E Brandao-Mello, et al.The New England Journal of Medicine|April 1, 2011
Boceprevir for previously treated chronic HCV genotype 1 infectionBruce R Bacon, Stuart C Gordon, Eric Lawitz, et al.Journal of Viral Hepatitis|May 22, 2020
Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohortVictor de Lédinghen, Clovis Lusivika-Nzinga, Jean-Pierre Bronowicki, et al.Gastroenterology|November 8, 2006
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 yearsStephanos J Hadziyannis, Nicolaos C Tassopoulos, E Jenny Heathcote, et al.Plos One|April 11, 2020
Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis BPatrick Marcellin, Qing Xie, Seung Woon Paik, et al.Cancer|July 17, 2015
Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis BW Ray Kim, Rohit Loomba, Thomas Berg, et al.Hepatology (Baltimore, Md.)|October 19, 2011
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis CStefan Zeuzem, Peter Buggisch, Kosh Agarwal, et al.Liver International : Official Journal of the International Association for the Study of the Liver|May 17, 2021
Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-lifeTarik Asselah, Dimitri Loureiro, Fréderic Le Gal, et al.Pageof 29